Apollo Hospitals Q3 net profit up 80 pc to Rs 90 crore
Healthcare major Apollo Hospitals Enterprise on Thursday reported a 80.36 per cent rise in consolidated net profit at Rs 89.96 crore for the quarter ended December on account of robust performance across verticals. The company had posted a net profit of Rs 49.87 crore in the corresponding period of the previous fiscal, Apollo Hospitals Enterprise said in a filing to the BSE.
Consolidated revenue from operations stood at Rs 2,911.74 crore for the quarter under consideration. It was at Rs 2,495.04 crore for the same period a year ago. The company's board has declared an interim dividend of Rs 3.25 per equity share of Rs 5 each for the financial year ending March 31, 2020, Apollo Hospitals Enterprise said.
"In addition to arming ourselves with newer offerings and treatment technologies, the resilience of our service model that offers comprehensive care across multiple centres and formats, is enabling us to maintain a focused trajectory of growth amidst a dynamic and fluid operating environment," Apollo Hospitals Chairman Prathap C Reddy said.
Even as Apollo Hospitals widens the suite of preventive healthcare offerings, "we are rapidly evolving our capabilities across key specialties such as oncology, neurosciences, orthopaedics and critical care to meet the healthcare challenges of the nation," he added.
As on December 31, 2019, Apollo Hospitals had over 7,470 operating beds across the network (excluding AHLL and managed beds), out of which 14 were new hospitals with 1,990 operating beds. The new hospitals are expected to see increase in volumes and utilisation going forward, the company said.
The total store network of standalone pharmacies as of December 31, 2019, stood at 3,700 operational stores, it added.
Apollo Health & Lifestyle Ltd (AHLL), a wholly owned subsidiary which houses the retail healthcare business of Apollo Hospitals, had 917 centers in total as of December 31, 2019, the company said.
Shares of Apollo Hospitals Enterprise on Thursday closed 1.41 per cent higher at Rs 1,707.80 per scrip on the BSE.
